☆ 4.6 Editorial Material

Treatment of myeloma: Cure vs control

MAYO CLINIC PROCEEDINGS (2008)

期刊

MAYO CLINIC PROCEEDINGS

卷 83, 期 10, 页码 1142-1145

出版社

ELSEVIER SCIENCE INC

DOI: 10.4065/83.10.1142

关键词

-

类别

Medicine, General & Internal

资金

NCI NIH HHS [R01 CA093842, CA100080, CA85818, P01 CA062242, CA93842, R01 CA100080, R21 CA085818, CA62242] Funding Source: Medline
NATIONAL CANCER INSTITUTE [P01CA062242, R01CA100080, R21CA085818, R01CA093842] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Roadmap to cure multiple myeloma

Paula Rodriguez-Otero, Bruno Paiva, Jesus F. San-Miguel

Summary: In order to achieve a cure for multiple myeloma, five complementary strategies are proposed: increasing knowledge about disease pathogenesis, using undetectable measurable residual disease as the new endpoint of therapy, treating disease causation instead of symptomatology, using the most active scheme, and investigating experimental therapies.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Article Health Care Sciences & Services

Steps towards a Multiple Myeloma Cure?

Alessandro Gozzetti, Monica Bocchia

Summary: The survival rate of multiple myeloma has increased in the past 20 years due to new treatments, improved clinical management, and a better understanding of the disease. Novel drugs and therapeutic strategies have allowed a considerable number of patients to achieve durable remission or even disease disappearance.

JOURNAL OF PERSONALIZED MEDICINE (2022)

添加到收藏夹

Article Hematology

Requirements for operational cure in multiple myeloma

Mohamad Mohty, Herve Avet-Loiseau, Jean-Luc Harousseau

Summary: With recent therapeutic advancements, operational cure for multiple myeloma is becoming a realistic goal. The correlation between MRD negativity and improved patient outcomes suggests MRD as a surrogate for potential long-term cure. Various parameters influence the value and impact of MRD, with different treatment approaches leading to potential operational cure in both younger and older patients.

BLOOD (2021)

添加到收藏夹

Review Oncology

Multiple Myeloma: Possible Cure from the Sea

Anita Capalbo, Chiara Lauritano

Summary: Multiple myeloma (MM) is a difficult-to-cure blood cancer, and although there are current treatments, scientists are exploring new options. Marine-derived drugs like BLENREP and Aplidin, as well as other natural products, show promise in MM treatment. These therapies include specific targeted molecules and compounds that deliver drugs to the correct cell targets using antibodies.

CANCERS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment

Gianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci

Summary: Multiple myeloma is a clinically heterogeneous disease caused by interactions between bone marrow-resident clonal plasma cells and the microenvironment. Recent advances in understanding these interactions have led to the development of novel drugs with immune-mediated mechanisms of action. These drugs have shown promising results in large clinical trials and are now being used in real-life management. However, the timing of drug introduction and management of adverse events are new challenges that require further experience to improve their use.

BIOMOLECULES (2022)

添加到收藏夹

Article Hematology

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

Noemi Puig, Maria-Teresa Contreras, Cristina Agullo, Joaquin Martinez-Lopez, Albert Oriol, Maria-Jesus Blanchard, Rafael Rios, Jesus Martin, Maria-Belen Inigo, Anna Sureda, Miguel-Teodoro Hernandez, Javier de la Rubia, Veronica Gonzalez-Calle, Isabel Krsnik, Valentin Cabanas, Luis Palomera, Jose-Maria Moraleda, Joan Bargay, Maria-Teresa Cedena, Bruno Paiva, Laura Rosinol, Joan Blade, Jesus San Miguel, Juan-Jose Lahuerta, Maria-Victoria Mateos

Summary: Monitoring of M-protein by EXENT&FLC-MS is more sensitive and accurate compared to IFE, providing better prediction of patients' outcome in MM.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Microbiology

Prevention, treatment and cure of HIV infection

Raphael J. Landovitz, Hyman Scott, Steven G. Deeks

Summary: In this Review, the authors explore the current state of HIV prevention and treatment, highlighting unmet needs and emerging tools. They discuss the combination of different approaches to achieve better outcomes, and describe recent progress in pre-exposure prophylaxis, vaccines, treatment, and cure. They emphasize the need for continued efforts to develop effective preventative vaccines and scalable cures, as the limitations of antiretroviral drugs become more apparent.

NATURE REVIEWS MICROBIOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Treatment to cure: Advancing AAV gene therapy manufacture

Paul Young

Summary: Advanced therapy medicinal products have extended the treatment paradigm to gene therapy, which modifies genes for therapeutic effect. Gene therapy has strong growth potential, especially using adeno-associated viruses (AAVs) for targeted delivery. However, manufacturing challenges exist in generating high-quality and efficacious viral vectors. Learning from established processes like monoclonal antibody production and embracing innovative approaches are crucial for scalable and cost-effective solutions. Ultimately, the goal is to turn treatment into a cure.

DRUG DISCOVERY TODAY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Treatment to cure: Advancing AAV gene therapy manufacture

Paul Young

Summary: Advanced therapy medicinal products have expanded the treatment options in the pharmaceutical industry by enabling gene therapy for potentially curative approaches, primarily using adeno-associated viruses (AAVs) for targeted delivery. However, manufacturing challenges exist in ensuring high quality and efficacy of AAV-based gene therapy products. Learning from established manufacturing processes like monoclonal antibodies (mAbs) can help develop scalable and cost-effective solutions. Future innovation and collaboration with regulatory agencies are essential for further advancements in gene therapy manufacturing and achieving the ultimate goal of cure.

DRUG DISCOVERY TODAY (2023)

添加到收藏夹

Review Immunology

Immunotherapy for the treatment of multiple myeloma

Leora S. Boussi, Zachary M. Avigan, Jacalyn Rosenblatt

Summary: Despite advances in treatment for multiple myeloma, understanding the mechanisms of immune evasion and resistance to therapy is critical for developing more effective treatments. Cellular adoptive therapy, particularly CAR T cell therapy, has shown promising results in refractory cases and may be a viable option for treatment.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Oncology

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Philippe Moreau, Shaji K. Kumar, Jesus San Miguel, Faith Davies, Elena Zamagni, Nizar Bahlis, Heinz Ludwig, Joseph Mikhael, Evangelos Terpos, Fredrik Schjesvold, Thomas Martin, Kwee Yong, Brian G. M. Durie, Thierry Facon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels van de Donk, Sagar Lonial, Michele Cavo, Sigurdur Y. Kristinsson, Suzanne Lentzsch, Roman Hajek, Kenneth C. Anderson, Cristina Joao, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafael Fonseca, Annette Vangsted, Katja Weisel, Rachid Baz, Vania Hungria, Jesus G. Berdeja, Fernando Leal da Costa, Angelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Blade, Xavier Leleu, Eloisa Riva, Peter Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf-Henrik Mellqvist, Dominik Dytfeld, Jean-Luc Harousseau, Hartmut Goldschmidt, Jacob Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksac, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah Holstein, Orhan Sezer, Simon Harrison, Hareth Nahi, Gordon Cook, Maria-Victoria Mateos, S. Vincent Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson

Summary: This policy review presents clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma, integrating drug access issues for patients in different income settings to improve patient outcomes in real-world practice.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Perspectives on the Treatment of Multiple Myeloma

Abdul Rafae, Frits van Rhee, Samer Al Hadidi

Summary: The treatment of multiple myeloma has significantly improved with the development of new therapies, but there remains a subset of high-risk patients with poor prognosis. Future clinical trials should focus on developing new treatments specifically for high-risk multiple myeloma.

ONCOLOGIST (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pathogenesis and Treatment of Myeloma-Related Bone Disease

Yuh-Ching Gau, Tsung-Jang Yeh, Chin-Mu Hsu, Samuel Yien Hsiao, Hui-Hua Hsiao

Summary: Multiple myeloma-related bone disease (MBD) is caused by an imbalance in the bone-remodeling process and involves various signaling pathways and molecules. Bisphosphonate and denosumab are currently the standard treatments, while novel bone-modifying therapies are being explored.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Improvement of hypertension control and left-ventricular function after cure of primary hyperparathyroidism

Izabela Karwacka, Piotr Kmiec, Sonia Kaniuka-Jakubowska, Izabela Pisowodzka, Marcin Fijalkowski, Krzysztof Sworczak

Summary: Cardiovascular mortality is higher in patients with primary hyperparathyroidism (PHPT) compared to the general population. The role of the renin-angiotensin-aldosterone system (RAAS) in cardiovascular pathology in PHPT is unclear, as is the effect of successful parathyroidectomy (PTX) on hypertension and left-ventricular dysfunction.

FRONTIERS IN ENDOCRINOLOGY (2023)

添加到收藏夹

Article Oncology

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Saad Z. Usmani, Maria-Victoria Mateos, Vania Hungria, Shinsuke Iida, Nizar J. Bahlis, Hareth Nahi, Hila Magen, Michele Cavo, Cyrille Hulin, Darrell White, Valerio De Stefano, John Fastenau, Mary Slavcev, Christoph Heuck, Xiang Qin, Huiling Pei, Tara Masterson, Kristen Lantz, Katharine S. Gries

Summary: In the COLUMBA study, patients receiving daratumumab subcutaneously had higher satisfaction with their cancer therapy compared to those receiving it intravenously. Around 40% of patients experienced changes in satisfaction domain scores exceeding the minimally important difference.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

Saurabh Zanwar, Matthew Ho, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Amie Fonder, Miriam Hobbs, Yi Hwa, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar

LEUKEMIA (2022)

添加到收藏夹

Letter Oncology

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

Nadine Abdallah, David Murray, Angela Dispenzieri, Prashant Kapoor, Morie A. Gertz, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Wilson Gonsalves, Eli Muchtar, Nelson Leung, David Dingli, Taxiarchis Kourelis, Rahma Warsame, Moritz Binder, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar

LEUKEMIA (2022)

添加到收藏夹

Letter Oncology

Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100

Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A. Kyle, Shaji K. Kumar

Summary: A retrospective study found that increased urine monoclonal protein (uMCP) excretion is associated with an increased risk of progression in patients with multiple myeloma (MM), especially when the ratio of involved to uninvolved free light chain (FLCr) is equal to or greater than 100. Therefore, conducting a diagnostic 24-hour urine assessment is important in determining the need for therapy in these patients.

LEUKEMIA (2022)

添加到收藏夹

Article Hematology

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

Charalampos Charalampous, Utkarsh Goel, Stephen M. Broski, David Dingli, Prashant Kapoor, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Francis Buadi, Lisa Hwa, Nelson Leung, Yi Lin, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Rahma Warsame, Amie Fonder, Miriam Hobbs, Moritz Binder, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

Summary: This study aimed to investigate the prognostic significance of PET/CT in newly diagnosed MM. The findings showed that PET/CT-negative patients had better outcomes in terms of TTNT and OS, and added significant value to hematologic response assessment at 6 months post-diagnosis.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method

Celine M. Vachon, Josiah Murray, Cristine Allmer, Dirk Larson, Aaron D. Norman, Jason P. Sinnwell, Angela Dispenzieri, Geffen Kleinstern, Alissa Visram, Robert A. Kyle, S. Vincent Rajkumar, Susan L. Slager, Shaji K. Kumar, David L. Murray

Summary: Mass-spectrometry (MS) assays can detect monoclonal gammopathy of undetermined significance (MGUS) at an earlier stage, and the prevalence of heavy chain MGUS is higher in African Americans and first-degree relatives of patients with hematologic disorders. The MALDI-TOF assay can identify more cases of MGUS compared to conventional gel-based methods, but the relative differences based on race, family history, and age are similar to prior studies.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis

Matthew Ho, Saurabh Zanwar, Francis K. Buadi, Sikander Ailawadhi, Jeremy Larsen, Leif Bergsagel, Moritz Binder, Asher Chanan-Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Wilson Gonsalves, Ronald S. Go, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Eli Muchtar, Vivek Roy, Taimur Sher, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi L. Hwa, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar

Summary: Patients with multiple myeloma have a lower efficacy from COVID-19 vaccination and a high rate of mortality from COVID-19 in hospitalized patients. The study found a relatively low infection rate but a quarter of the COVID-19 infections were severe. Treatment with CD38 antibody, cardiac and pulmonary comorbidities were independent predictors for ICU admission. Cardiac comorbidity was an independent predictor of mortality, while MM/AL in remission was associated with lower mortality.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Article Oncology

A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

Marco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, Angelica Macauda, Juan Sainz, Mitchell J. Machiela, Malwina Rybicka-Ramos, Aaron D. Norman, Agata Tyczynska, Stephen J. Chanock, Torben Barington, Shaji K. Kumar, Parveen Bhatti, Wendy Cozen, Elizabeth E. Brown, Anna Suska, Eva K. Haastrup, Robert Z. Orlowski, Marek Dudzinski, Ramon Garcia-Sanz, Marcin Kruszewski, Joaquin Martinez-Lopez, Katia Beider, Elzbieta Iskierka-Jazdzewska, Matteo Pelosini, Sonja Berndt, Malgorzata Razny, Krzysztof Jamroziak, S. Vincent Rajkumar, Artur Jurczyszyn, Annette Juul Vangsted, Pilar Garrido Collado, Ulla Vogel, Jonathan N. Hofmann, Mario Petrini, Aleksandra Butrym, Susan L. Slager, Elad Ziv, Edyta Subocz, Graham G. Giles, Niels Frost Andersen, Grzegorz Mazur, Marzena Watek, Fabienne Lesueur, Michelle A. T. Hildebrandt, Daria Zawirska, Lene Hyldahl Ebbesen, Herlander Marques, Federica Gemignani, Charles Dumontet, Judit Varkonyi, Gabriele Buda, Arnon Nagler, Agnieszka Druzd-Sitek, Xifeng Wu, Katalin Kadar, Nicola J. Camp, Norbert Grzasko, Rosalie G. Waller, Celine Vachon, Federico Canzian, Daniele Campa

Summary: The aim of this study was to identify novel pleiotropic variants involved in multiple myeloma (MM) risk. Through analysis of 28,684 single nucleotide polymorphisms (SNPs), DNAJB4-rs34517439-A was found to be associated with an increased risk of developing MM.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Article Hematology

Survival trends in young patients with Waldenstrom macroglobulinemia: Over five decades of experience

Karan L. Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L. King, Rong He, Wilson Gonsalves, David Inwards, Thomas E. Witzig, Abhisek Swaika, Tania Jain, Nelson Leung, Sikander Ailawadhi, Craig B. Reeder, Martha Q. Lacy, S. Vincent Rajkumar, Shaji Kumar, Robert A. Kyle, Morie A. Gertz, Stephen M. Ansell, Prashant Kapoor

Summary: Waldenstrom macroglobulinemia (WM) is a rare, indolent lymphoma that mostly affects the elderly. A study compared young WM patients to their older counterparts and found that young patients have lower overall survival and higher death attributable to WM. The treatment strategies for WM have not improved the outcome of young patients, and the impact of Bruton tyrosine kinase inhibitors on this patient population is still unknown.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up

Nadine Abdallah, Angela Dispenzieri, Eli Muchtar, Francis K. K. Buadi, Prashant Kapoor, Martha Q. Q. Lacy, Yi L. L. Hwa, Amie Fonder, Miriam A. A. Hobbs, Suzanne R. R. Hayman, Nelson Leung, David Dingli, Ronald S. S. Go, Yi Lin, Wilson I. I. Gonsalves, Moritz Binder, Taxiarchis Kourelis, Rahma Warsame, Robert A. A. Kyle, S. Vincent Rajkumar, Morie A. A. Gertz, Shaji K. K. Kumar

Summary: After long-term follow-up, there is no clear evidence to support the benefit of doxycycline in the post-transplant setting.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

添加到收藏夹

Article Oncology

Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma

Bharat Nandakumar, Francis Baffour, Nadine H. H. Abdallah, Shaji K. K. Kumar, Angela Dispenzieri, Francis K. K. Buadi, David Dingli, Martha Q. Q. Lacy, Suzanne R. R. Hayman, Prashant Kapoor, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Eli Muchtar, Rahma Warsame, Taxiarchis V. V. Kourelis, Ronald S. S. Go, Robert A. A. Kyle, Morie A. A. Gertz, S. Vincent Rajkumar, Jason Klug, Panagiotis Korfiatis, Wilson I. I. Gonsalves

Summary: Using a deep learning-based segmentation approach, sarcopenia can be accurately detected and measured in clinical computed tomography (CT) images of patients with newly diagnosed multiple myeloma (NDMM). Sarcopenia significantly affects overall survival in NDMM patients and is an independent adverse prognostic factor.

CANCER (2023)

添加到收藏夹

Editorial Material Oncology

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based m protein assessment

Jean-Sebastien Claveau, David L. Murray, Angela Dispenzieri, Prashant Kapoor, Moritz Binder, Francis Buadi, David Dingli, Amie Fonder, Morie Gertz, Wilson Gonsalves, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa, Taxiarchis Kourelis, Martha Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A. Kyle, Vincent Rajkumar, Shaji K. Kumar

LEUKEMIA (2023)

添加到收藏夹

Article Oncology

Multiple myeloma with acute light chain cast nephropathy

Nelson Leung, S. Vincent Rajkumar

Summary: Light chain cast nephropathy (LCCN) is a significant cause of acute kidney injury (AKI) in patients with multiple myeloma (MM) and is now considered as a defining event of myeloma. While long-term prognosis has improved, short-term mortality remains higher in patients with LCCN if renal failure is not reversed. Rapid reduction of involved serum free light chain is critical for renal function recovery. Treatment algorithm for MM patients with biopsy-proven LCCN or ruling out other causes of AKI is provided based on randomized trial data whenever available. Clinical trial enrollment is recommended prior to following the treatment algorithm.

BLOOD CANCER JOURNAL (2023)

添加到收藏夹

Article Oncology

Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance

Alexander J. Ryu, Shaji Kumar, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Thomas C. Kingsley

Summary: This study used machine learning and electronic health record data to identify potential drug candidates for modifying the progression risk of MGUS. Various medications were found to be significantly associated with the risk of MGUS progression, which could inform future prospective studies.

BLOOD CANCER JOURNAL (2023)

添加到收藏夹

Letter Oncology

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians

Rahul Banerjee, Bo Wang, Larry D. Anderson, Georgia Mccaughan, Nikita Mehra, Andrew J. Cowan, S. Vincent Rajkumar, Gurbakhash Kaur

BLOOD CANCER JOURNAL (2023)

添加到收藏夹

Meeting Abstract Oncology

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry based M protein assessment

Jean-Sebastien Claveau, David Murray, Angela Dispenzieri, Prashant Kapoor, Moritz Binder, Francis Buadi, David Dingli, Amie Fonder, Morie Gertz, Wilson Gonsalves, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa, Taxiarchis Kourelis, Martha Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert Kyle, Vincent Rajkumar, Shaji Kumar

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.